scholarly journals Are caveolin-1 minor alleles more likely to be risk alleles in insulin resistance mechanisms in metabolic diseases?

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Faezeh Abaj ◽  
Said Abdul Ghafour Saeedy ◽  
Khadijeh Mirzaei
Keyword(s):  
Insulin Resistance ◽  
Metabolic Diseases ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Resistance Mechanisms ◽  
Minor Allele ◽  
Lipoprotein Cholesterol ◽  
Obese Women ◽  
Caveolin 1 ◽  
Fat Composition

Abstract Objectives Obesity and insulin resistance (IR) are interrelated in a range of ways. The IR-obesity relationship is not a cause-and-effect association. Molecular biology research has made tremendous strides in discovering contributors to find this association. Genes that control adipocyte function such as caveolin-1 (CAV1); probably interact in the pathogenesis of human IR in this context. The involvement of CAV1 in glucose/lipid homeostasis is revealed and could modify the signaling of the insulin receptor. We examined the association between CAV1 and insulin signaling in modifying dyslipidemia and fat composition in overweight and obese women with a prevalent variant in the CAV1 gene. Results Minor allele carriers were slightly older and had higher BMI (p = 0.02), FMI (p = 0.006), and VLF (p = 0.01) values; and tended to have lower total cholesterol TC (p = 0.04), low-density lipoprotein cholesterol (LDL-C) (p = 0.001) and high-density lipoprotein cholesterol (HDL-C) (p = 0.003). HOMA-IR levels predicted fat mass index (FMI) 0.47 (0.08, 0.87), visceral fat level (VFL) 0.65 (0.23, 1.07), TC 6.82 (1.76, 11.88) and HDL-C − 1.663 (− 3.11, − 0.214) only between minor allele carriers in adjusted models. (β, CI). Our results cast a new light on the IR mechanism and future studies will elucidate the clinical relevance of CAV1-IR in patients with dyslipidemia and high fat composition.

scholarly journals Are Caveolin-1 minor alleles more likely to be risk alleles in IR mechanisms in metabolic diseases?

2021 ◽  
Author(s):  
Faezeh Abaj ◽  
Said Abdul Ghafour Saeedy ◽  
Khadijeh Mirzaei
Keyword(s):  
Metabolic Diseases ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Obese Women ◽  
Caveolin 1 ◽  
Risk Alleles ◽  
Fat Composition ◽  
Fat Level ◽  
The Relationship

Abstract Objectives Associations are present between insulin resistance (IR) and dyslipidemia and cardiometabolic factors. Caveolin-1 (CAV1) is involved in glucose/lipid homeostasis and may modulate IR signaling. We investigated the relationship between CAV1 and IR signaling in modulating dyslipidemia and fat composition in overweight and obese women with a prevalent variant in the CAV1 gene. Results There were no statistical differences in FPG, plasma insulin, and HOMA-IR (p > 0.05) between CAV1 variants. Individuals with AA and AG alleles were slightly older and had higher BMI, FMI, and VLF values; and tended to have lower total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) (p < 0.05). HOMA-IR levels predicted fat mass index (FMI) 0.47 (0.08,0.87), visceral fat level (VFL) 0.65 (0.23,1.07), TC 6.82 (1.76,11.88) and HDL-C -1.663 (-3.11, -0.214) only between minor allele carriers in unadjusted and adjusted models. (, CI (P < 0.01). Our r

Pioglitazone — current profile

2002 ◽  
Vol 2 (1_suppl) ◽  
pp. S18-S23 ◽  
Author(s):  
Paolo Brunetti
Keyword(s):  
Insulin Resistance ◽  
Clinical Trials ◽  
Cell Function ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Current Profile ◽  
Combination Studies

Ploglitazone is a thiazolidinedione that specifically reduces insulin resistance in type 2 diabetes. It has been thoroughly investigated in clinical trials and since its market introduction in 1999 has been prescribed to many patients worldwide. In both monotherapy and combination therapy controlled trials, pioglitazone has proved to be an effective anti-hyperglycaemic agent, reducing fasting plasma glucose and displaying dose-dependent, long-term reductions in glycosylated haemoglobin (HbA1C) compared with placebo. Furthermore, in combination studies, insulin resistance and beta-cell function were significantly improved over baseline and placebo, as measured by HOMA. Pioglitazone also significantly reduced the levels of circulating triglycerides and increased high-density lipoprotein cholesterol without affecting total or low-density lipoprotein cholesterol. In all clinical trials, pioglitazone has been well-tolerated. It may be that the effects of pioglitazone on diabetic dyslipidaemia are at least as important as its effects on lowering blood glucose.

scholarly journals The association of laminin levels with insulin resistance and non-alcoholic hepatosteatosis

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Özgür Altun ◽  
Yücel Arman ◽  
Şengül Aydın Yoldemir ◽  
Ayşe Selcen Pala ◽  
Perihan Özkan Gümüşkaya ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Basement Membrane ◽  
Low Density Lipoprotein ◽  
Critical Role ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Insulin Effect ◽  
Study Results

Abstract Background Laminin, one of the largest glycoproteins of the basement membrane, is an important component of the extracellular matrix. Functions of the basement membrane include regulation of cell signaling behaviors and structural support. Laminin plays a critical role in the regulation of insulin action in muscle, liver, and adipose tissue. The study mainly investigates an association between the change in serum laminin levels and insulin resistance and non-alcoholic hepatosteatosis. Methods This prospective study included a total of 90 participants; 60 patients diagnosed with Grade 2–3 non-alcoholic hepatosteatosis and 30 age- and sex-matched healthy controls between December 2019 and December 2020. Routine laboratory tests including glucose, insulin, homeostatic model of assessment-insulin resistance (HOMA-IR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and C-reactive protein and laminin levels were measured in the serum of the patient and control groups. Enzyme-linked immunosorbent assay was used for the measurement of laminin levels. Results The median serum laminin levels were lower in patients with hepatic steatosis, compared to the control group (72 ng/L vs. 82 ng/L, respectively; p = 0.003). In the patients with insulin resistance, median laminin levels were lower, regardless of the presence of non-alcoholic hepatosteatosis (67 ng/L vs. 85 ng/L, respectively; p = 0.007). There was a weak, negative correlation between the laminin levels and HOMA-IR. Conclusions Our study results suggest that, although there is no exact link between laminin and non-alcoholic hepatosteatosis, serum laminin levels are lower in patients with insulin resistance by regulating the insulin effect through integrins.

scholarly journals Pediatric Loss-of-Control Eating and Anxiety in Relation to Components of Metabolic Syndrome

2018 ◽  
Vol 44 (2) ◽  
pp. 220-228 ◽  
Author(s):  
Meghan E Byrne ◽  
Marian Tanofsky-Kraff ◽  
Nichole R Kelly ◽  
Anne Claire Grammer ◽  
Manuela Jaramillo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Treatment Seeking ◽  
Loss Of Control ◽  
Convenience Sample ◽  
Air Displacement Plethysmography ◽  
The Relationship

Abstract Objective Pediatric loss-of-control (LOC) eating is associated with, and predictive of, gains in adiposity and adverse metabolic outcomes. In addition, some preliminary data suggest that anxiety may exacerbate the relationship of LOC eating with weight and metabolic syndrome (MetS)-related measures. We therefore examined whether anxiety moderated the relationship between LOC eating and body mass index z (BMIz), adiposity, and MetS-related measures in youth. Methods A convenience sample of non-treatment-seeking boys and girls of varying weight strata were interviewed to determine the presence of LOC eating and completed a questionnaire assessing trait anxiety. BMIz and MetS-related measures (blood pressure, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glucose, and insulin) were measured after an overnight fast. Adiposity was assessed by air displacement plethysmography or dual-energy x-ray absorptiometry. Analyses adjusted for age, sex, race, height, fat mass, and depressive symptoms, as appropriate. Results In all, 379 youths (13.0 ± 2.8 years; 53% female; BMIz = 0.8 ± 1.1; 22% with LOC eating) were studied. Anxiety was not significantly related to BMIz, adiposity, or MetS-related measures. However, anxiety and LOC eating interacted such that only among youth with LOC eating, anxiety was positively associated with fasting insulin (p = .02) and insulin resistance (p = .01). The interaction of anxiety and LOC eating was not significantly related to BMIz, adiposity, or any other MetS-related measure (ps = ns). Conclusions Only among non-treatment-seeking youth with LOC eating, anxiety may be associated with increased insulin secretion and insulin resistance. Longitudinal studies are required to confirm these findings and explore mechanisms for these relationships.

scholarly journals Serum osteoprotegerin and cardiometabolic risk factors in overweight and obese children

2021 ◽  
Author(s):  
Małgorzata Rumińska ◽  
Ewelina Witkowska-Sędek ◽  
Anna Stelmaszczyk-Emmel ◽  
Anna Majcher ◽  
Anna Kucharska ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Cardiometabolic Risk ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cardiometabolic Risk Factors ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Obese Children ◽  
Low Density Lipoprotein Cholesterol

IntroductionOsteoprotegerin has been shown to play a role in vascular calcification, atherosclerosis and the pathogenesis of cardiovascular diseases. We aimed to evaluate whether excess fat mass affects serum osteoprotegerin concentrations and to evaluate its associations with chosen cardiometabolic risk factors in overweight and obese children.Material and methodsWe enrolled 105 children ranging from 7.0 to 17.8 years of age. Among them 70 individuals were overweight and obese, and 35 were healthy with normal physical parameters. In all patients, anthropometric measurements and laboratory tests were performed. Atherogenic and insulin resistance indices were calculated.ResultsWe did not find any differences in serum osteoprotegerin concentrations between overweight and obese children and their lean peers. In all studied patients, together with elevated quartiles of osteoprotegerin concentration, insulin resistance status decreased, and low-density lipoprotein cholesterol concentration increased. In the group of overweight and obese children osteoprotegerin was associated with low-density lipoprotein cholesterol, total cholesterol, and non high-density lipoprotein cholesterol. In the multiple linear regression analysis osteoprotegerin correlated only with low-density lipoprotein cholesterol (β = 0.140, p = 0.005).ConclusionsInsulin resistance and lipid profile seem to influence circulating osteoprotegerin levels, but most likely needs more time to change its concentration in overweight and obese patients. The association of osteoprotegerin with low-density lipoprotein cholesterol may suggest its link with atherogenesis.

NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study

2010 ◽  
Vol 35 (6) ◽  
pp. 773-782 ◽  
Author(s):  
Shuguang Li ◽  
Laetitia Guerin-Deremaux ◽  
Marine Pochat ◽  
Daniel Wils ◽  
Cheryl Reifer ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Test Group ◽  
Lipoprotein Cholesterol ◽  
Controlled Study ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Double Blind

The influence of dietary fiber on determinants of metabolic syndrome is controversial. The objective of this study was to determine the effects of NUTRIOSE supplementation on insulin resistance and the determinants of metabolic syndrome in overweight men. In this double-blind, randomized, placebo-controlled study, we supplemented the diets of overweight Chinese men with 250 mL of fruit juice that contained NUTRIOSE (Test group: n = 60, age = 30.4 ± 4.3 years, body mass index (BMI) = 24.5 ± 0.2 kg·m–2) or a maltodextrin placebo (Control group: n = 60, age = 31.6 ± 4.1 years, BMI = 24.5 ± 0.3 kg·m–2) at a dosage of 17 g twice daily for 12 weeks. Daily caloric intake, body composition, blood chemistry, and blood pressure were evaluated every 4 weeks during the trial. Test subjects consumed fewer calories per day and had greater reductions in body weight, BMI, body fat percentage, and waist circumference than Control subjects. All markers of glucose metabolism improved in the Test group, with increases in adiponectin and reductions in glucose, insulin, homeostasis model assessment-estimated insulin resistance, glycosylated hemoglobin, and glycated albumin (all p < 0.01). Similarly, all lipid measures improved with increases in high-density lipoprotein cholesterol and reductions in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, and triglycerides (all p < 0.01). No changes were observed in systolic blood pressure between groups. Most components of glucose metabolism and the lipid profile were significantly better in the Test than in the Control subjects. No adverse events or gastrointestinal complaints were reported in either group. Supplementation with NUTRIOSE for 12 weeks is well tolerated, lowers insulin resistance, and improves determinants of metabolic syndrome in overweight men.

Sign in / Sign up

Export Citation Format

Share Document